Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
A study compared treatment outcomes among those seen at standard intervals with those seen for just two clinic visits.
The generally false presumption that they won’t adhere to the regimen is often used to deny coverage for hep C medications.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
State legislators will no longer push for a lifetime ban on hepatitis C treatment for people on Medicaid who do not adhere to treatment.
Sometime last week I appear to have missed my hep C meds. What helps you remember to take the meds?
Taking your medications is one of the most important things that you can do, along with seeing your physician.
Pharmacy data collected during the past nine months shows the dropout rate has been roughly four times that observed in clinical trials.
A summary of major findings presented at AIDS 2014.
Those taking AbbVieâ€™s triple combination therapy, plus ribavirin, to treat hepatitis C showed high rates of adherence to the mediations...
Higher levels of adherence to hep C treatment helps maximize efficacy in people coinfected with HIV.
Patients were enthusiastic about open access to primary care provider visit notes.
’Real world’ data from pharmacies show the new hepatitis C protease inhibitors Incivek (telaprevir) and Victrelis (boceprevir) are working as...
The approval of two hepatitis C protease inhibitors, the first evidence of interferon-free regimens curing hep C, and more...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.